Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Robert Hassan El-Maraghi
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Pascal Hammel
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Volker Heinemann
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Volker Kunzmann
Consultant or Advisory Role - Celgene
Javier Sastre
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Roche; Sanofi
Teresa Macarulla
No relevant relationships to disclose
Luis Teixeira
No relevant relationships to disclose
Giampaolo Tortora
Research Funding - Celgene
Jean Luc Van Laethem
No relevant relationships to disclose
Darryl Neil Penenberg
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Brian Lu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Alfredo Romano
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene (I)
Research Funding - TGen